Antibody drug conjugates (ADCs) are a unique class of therapeutic anti-cancer agents in which cytotoxic drugs are covalently conjugated to a monoclonal antibody through small chemical linkers. The idea behind an ADC is the targeted delivery of cytotoxins to tumors using blood circulation as the transportation media. Thus, the plasma stability of an ADC is of crucial importance since it dictates the off-target drug release and directly affect its in vivo efficacy and safety. Creative biolabs fully understands the role of plasma stability in the ADC development and we have adopted an advanced analytical system to enable its accurate evaluation.